Organization | Clinigen, Inc.

Clinigen, Inc. Report issue

For profit Phase 2

Founded: Burton Upon Trent United Kingdom (2008)

Organization Overview

First Clinical Trial

2018

NCT03501381

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Clinigen, Inc.

Active Ingredients

Marketed Drugs (1)

aldesleukin (Proleukin) (1992)

Drugs in Phase 2 Trials (4)

aldesleukin (Proleukin) (2 trials)

entinostat (1 trial)

ipilimumab (yervoy) (1 trial)

nivolumab (opdivo) (1 trial)

Drugs in Other Trials (3)

anifrolumab (Saphnelo) (1 trial)

maralixibat (LIVMARLI) (1 trial)

tebentafusp (Kimmtrak) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Melanoma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 7